Lykos Therapeutics Strategic Reorganization Following FDA’s Decision Rejecting MDMA For PTSD Treatment
Lykos Therapeutics has announced a strategic reorganization in response to the recent FDA decision regarding its new drug application for MDMA capsules – also known as Ecstasy or Molly – intended for treating post-traumatic stress disorder (PTSD) in adults.
New Senior Medical Advisor
As the company recently reported, the restructuring includes the appointment of Dr. David Hough, a seasoned pharmaceutical industry veteran and former VP of Research and Development at Janssen, as the senior medical advisor. Dr. Hough will lead Lykos’ clinical development program and oversee engagement with the FDA as the company prepares to resubmit its application for MDMA. “My hope is to build on the strong foundation Lykos has created and leverage my experience in the industry to ensure a productive …